<DOC>
	<DOCNO>NCT01840605</DOCNO>
	<brief_summary>The objective study verify non-inferiority TAU-284 ketotifen fumarate dry syrup change severity pruritus treatment period .</brief_summary>
	<brief_title>A Confirmatory Study TAU-284 Pediatric Patients With Atopic Dermatitis</brief_title>
	<detailed_description>This randomize , double-blind , parallel-group comparative study demonstrate noninferiority TAU-284 ketotifen fumarate pediatric patient atopic dermatitis , assess primary endpoint change baseline pruritus score 2-week treatment TAU-284 ( 20 mg/day ) ketotifen fumarate dry syrup ( 2 g/day ) ; investigate safety , plasma concentration TAU-284 .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<criteria>Patients age 7 15 year Patients give assent whose legal guardian give informed consent Outpatients Patients diagnose atopic dermatitis Patients require treatment topical corticosteroid area face , head neck Patients whose diary properly maintain Patients 2 grade pruritus score Patients bronchial asthma require concomitant use corticosteroid Patients undergo specific desensitization therapy nonspecific immunomodulation therapy phototherapy Patients current previous history drug hypersensitivity Patients treat Bepotastine besilate past Patients ; skin infection , zooparasite scabies pediculosis ; eczematous otitis externa perforation eardrum ; dermal ulcer , profound heat burn frostbite severity high grade 2 ; area topical corticosteroid apply Patients spastic disease epilepsy Patients concurrently renal function abnormality may cause safety problem Patients give consent use birth control Pregnant patient , risk pregnancy breastfeed Patients participate clinical trial last 12 week</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>